2024/10/03 更新

写真a

イケスエ ヒロアキ
池末 裕明
IKESUE Hiroaki
所属
医学部附属病院 薬剤部 教授
大学院担当
大学院医学系研究科
職名
教授

研究キーワード 5

  1. 医療薬学

  2. 薬物療法

  3. がん薬物療法

  4. 有害事象

  5. 多職種協働

研究分野 1

  1. ライフサイエンス / 医療薬学

経歴 4

  1. 名古屋大学医学部附属病院   薬剤部   教授・薬剤部長

    2024年9月 - 現在

  2. 神戸市立医療センター中央市民病院   薬剤部   副部長

    2020年4月 - 2024年8月

  3. 神戸市立医療センター中央市民病院   薬剤部   副部長代行

    2016年4月 - 2020年3月

  4. 九州大学病院   薬剤部

    1999年4月 - 2016年3月

学歴 1

  1. 九州大学   薬学部

    - 1998年3月

所属学協会 17

  1. 日本在宅薬学会

    2022年 - 現在

  2. 日本乳癌学会

    2022年 - 現在

  3. Multinational Association of Supportive Care in Cancer (MASCC)

    2020年 - 現在

  4. 日本臨床栄養代謝学会

    2019年 - 現在

  5. 日本注射薬臨床情報学会

    2018年 - 現在

  6. 日本がんサポーティブケア学会

    2018年 - 現在

  7. 日本TDM学会

    2016年 - 現在

  8. 日本臨床薬理学会

    2015年 - 現在

  9. 日本臨床薬理学会

    2013年 - 現在

  10. 日本がん薬剤学会

    2013年 - 現在

  11. 日本臨床腫瘍薬学会

    2011年 - 現在

  12. 日本緩和医療薬学会

    2010年 - 現在

  13. 日本癌治療学会

    2008年 - 現在

  14. 日本薬学会

    2006年 - 現在

  15. American Society of Health-System Pharmacists (ASHP)

    2006年 - 現在

  16. 日本臨床腫瘍学会

    2005年 - 現在

  17. 日本医療薬学会

    2002年 - 現在

▼全件表示

委員歴 7

  1. 日本医療薬学会   専門薬剤師制度小委員会委員  

    2023年 - 現在   

      詳細を見る

    団体区分:学協会

  2. 日本がん薬剤学会   研究推進委員会委員長  

    2022年 - 現在   

      詳細を見る

    団体区分:学協会

  3. 日本医療薬学会   地域薬学ケア専門薬剤師研修小委員会委員  

    2022年 - 現在   

  4. 日本癌治療学会   教育委員会委員  

    2020年 - 現在   

  5. 日本医療薬学会   JPHCS編集委員会委員  

    2020年 - 現在   

      詳細を見る

    団体区分:学協会

  6. 日本医療薬学会   がん専門薬剤師能力向上小委員会委員  

    2019年 - 現在   

      詳細を見る

    団体区分:学協会

  7. 日本臨床腫瘍薬学会   会誌編集委員会委員  

    2018年 - 現在   

      詳細を見る

    団体区分:学協会

▼全件表示

受賞 4

  1. 学術賞

    2023年   日本医療薬学会   がん薬物療法における多職種協働による臨床薬剤業務のアウトカム評価に関する研究

    池末裕明

  2. Honourable Mention, Hospital Pharmacy Section

    2014年   The 74th FIP World Congress of Pharmacy and Pharmaceutical Sciences 2014   Efficacy and safety of aprepitant in Japanese patients receiving high-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation

    Hiroaki Ikesue, Mayako Uchida, Kimitaka Suetsugu, Kenichiro Nagata, Nobuaki Egashira, Satohiro Masuda

  3. 奨励賞

    2005年   日本医療薬学会   がん化学療法ワークシートの開発に関する研究

    池末裕明

  4. 学術奨励賞

    2004年   日本病院薬剤師会   癌化学療法における薬剤管理指導業務-副作用の発現予測による質的 向上並びに効率化-

    池末裕明

 

論文 72

  1. Risk Evaluation of Proton Pump Inhibitors for Panitumumab-Related Hypomagnesemia in Patients with Metastatic Colorectal Cancer

    Hideyuki Katsura, Yukio Suga, Anna Kubo, Hayato Sugimura, Kaname Kumatani, Kazunobu Haruki, Miwa Yonezawa, Ayaka Narita, Rei Ishijima, Hiroaki Ikesue, Hitomi Toi, Naoko Takata

    Biological and Pharmaceutical Bulletin   47 巻 ( 1 ) 頁: 98 - 103   2024年1月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Pharmaceutical Society of Japan  

    DOI: 10.1248/bpb.b23-00641

  2. Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma

    Kenta Yamaoka, Kei Irie, Nobuhiro Hiramoto, Masaki Hirabatake, Hiroaki Ikesue, Tohru Hashida, Tadashi Shimizu, Takayuki Ishikawa, Nobuyuki Muroi

    Investigational New Drugs   41 巻 ( 5 ) 頁: 761 - 767   2023年9月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    Abstract

    The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. Recently, a subcutaneous formulation (SC) of daratumumab, which has fewer infusion reactions and shorter administration time, was approved. However, because SC has a fixed dose, overdosing is a concern for patients with low body weights. In this study, we investigated the safety and blood levels of daratumumab after switching from IV to SC in patients with multiple myeloma (MM). Patients who switched from IV to SC of daratumumab between June 2021 and May 2022 at Kobe City Medical Center General Hospital were included in the study. Blood daratumumab levels were measured using liquid chromatography-tandem mass spectrometry. Safety after switching from IV to SC was evaluated for six months and graded according to the Common Terminology Criteria for Adverse Events, version 5.0. The median body weight of ten patients included in the analysis was 57.4 kg (range: 45.0–74.4). Blood daratumumab levels were significantly increased after switching to SC (p = 0.002); median through concentration at the last IV dose was 403.6 μg/mL (range: 96.3–776.3) and that at the third SC dose was 557.1 μg/mL (range: 288.3–997.2). Grade 1–2 injection site reactions were observed in six patients (60.0%) after switching to SC. A new grade 3 adverse event was observed in only one patient (neutropenia). The blood levels of daratumumab were significantly increased after switching from IV to SC in patients with MM; however, the dosage was tolerable.

    DOI: 10.1007/s10637-023-01392-1

    その他リンク: https://link.springer.com/article/10.1007/s10637-023-01392-1/fulltext.html

  3. Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication

    Fumiaki Tanaka, Kei Irie, Nobuyuki Fukui, Ryo Horii, Hirotoshi Imamura, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Nobuyuki Sakai, Tohru Hashida

    Therapeutic Drug Monitoring     2023年8月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Ovid Technologies (Wolters Kluwer Health)  

    Background:

    Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma. However, the pharmacokinetics of TMZ to establish a treatment strategy for patients undergoing hemodialysis (HD) remain unclear. In this case report, we evaluated the pharmacokinetics and HD removal rate of TMZ in a patient with glioblastoma undergoing HD to determine optimal dosing of TMZ.

    Methods:

    A 78-year-old man with glioblastoma who underwent HD 3 times a week was treated with TMZ concomitant with radiotherapy. One dose of TMZ was prescribed at 75 mg/m<sup>2</sup> on the day before HD and another dose of 37.5 mg/m<sup>2</sup> on the day before non-HD. Peak and trough concentrations (1 hour and 12 hours after dosing, respectively) were evaluated before HD and on non-HD days. HD removal rate of TMZ was calculated based on the predialyzer and postdialyzer plasma concentrations. Furthermore, the TMZ plasma concentrations were measured using liquid chromatography–tandem mass spectrometry.

    Results:

    The mean plasma peak and trough concentrations ± SD after 75 mg/m<sup>2</sup> TMZ were 2917 ± 914 and 108 ± 17.6 ng/mL, respectively. Those after 37.5 mg/m<sup>2</sup> TMZ dosage were 1305 ± 650 and 53.8 ± 11.8 ng/mL, respectively. The mean HD TMZ removal rate was 84.9 ± 1.9%.

    Conclusions:

    TMZ was tolerable in patients undergoing HD. Based on the data from a single individual pharmacokinetic perspective, the pharmacokinetics of TMZ in this patient undergoing HD were comparable with those observed in patients with normal renal function. In addition, it may be reasonable to administer TMZ after HD because of the high HD removal rate.

    DOI: 10.1097/ftd.0000000000001125

  4. Pharmacist–Urologist Collaborative Management for Patients with Renal Cell Carcinoma Receiving Pazopanib Monotherapy

    Masaki Hirabatake, Hiroaki Ikesue, Shintaro Yoshino, Mayu Morimoto, Toshinari Yamasaki, Tohru Hashida, Mutsushi Kawakita, Nobuyuki Muroi

    Biological and Pharmaceutical Bulletin   46 巻 ( 8 ) 頁: 1065 - 1071   2023年8月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Pharmaceutical Society of Japan  

    DOI: 10.1248/bpb.b22-00917

  5. Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study

    Satoshi Dote, Eiji Shiwaku, Emiko Kohno, Ryohei Fujii, Keiji Mashimo, Naomi Morimoto, Masaki Yoshino, Naoki Odaira, Hiroaki Ikesue, Masaki Hirabatake, Katsuyuki Takahashi, Masaya Takahashi, Mari Takagi, Satoshi Nishiuma, Kaori Ito, Akane Shimato, Shoji Itakura, Yoshitaka Takahashi, Yutaka Negoro, Mina Shigemori, Hiroyuki Watanabe, Dai Hayasaka, Masahiko Nakao, Misaki Tasaka, Emi Goto, Noriaki Kataoka, Ayako Yokomizo, Ayako Kobayashi, Yoko Nakata, Mafumi Miyake, Yaeko Hayashi, Yoshie Yamamoto, Taiki Hirata, Kanako Azuma, Katsuya Makihara, Rino Fukui, Akira Tokutome, Keiji Yagisawa, Shinji Honda, Yuji Meguro, Shota Suzuki, Daisuke Yamaguchi, Hitomi Miyata, Yuka Kobayashi

    International Journal of Clinical Oncology   28 巻 ( 8 ) 頁: 1054 - 1062   2023年6月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    DOI: 10.1007/s10147-023-02357-3

    その他リンク: https://link.springer.com/article/10.1007/s10147-023-02357-3/fulltext.html

  6. 冠動脈バイパス術が施行された2型糖尿病患者におけるSGLT2阻害薬の術後アシドーシスに与える影響 査読有り

    増本憲生, 豊田紗和子, 土肥麻貴子, 入江慶, 奥貞智, 池末裕明, 橋田亨, 松岡直樹, 室井延之

    くすりと糖尿病   13 巻 ( 1 ) 頁: 31 - 37   2023年6月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

  7. Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite <scp>GS</scp>‐441524 in patients with moderate and severe <scp>COVID</scp>‐19

    Ryo Tamura, Kei Irie, Atsushi Nakagawa, Hirohito Muroi, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida

    CPT: Pharmacometrics &amp; Systems Pharmacology   12 巻 ( 4 ) 頁: 513 - 521   2023年2月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Abstract

    Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major metabolite, GS‐441524, were evaluated using a population PK (PopPK) approach to understand the PK aspect and exposure–clinical outcome relationship. The serum concentrations of remdesivir and GS‐441524 (102 points in 39 patients) were measured using liquid chromatography–tandem mass spectrometry. All patients received 200 mg remdesivir on the first day, followed by 100 mg on 2–5 days, except for one patient who discontinued remdesivir on day 4. The median (range) age, body surface area, and estimated glomerular filtration rate (eGFR) were 70 (42–85), 1.74 m<sup>2</sup> (1.36–2.03), and 68 mL/min/1.73 m<sup>2</sup> (33–113), respectively. A compartment model with first‐order elimination combined with remdesivir and GS‐441524 was used for nonlinear mixed‐effects model analysis. Remdesivir was rapidly eliminated after infusion, whereas GS‐441524 was eliminated relatively slowly (half‐time = 17.1 h). The estimated apparent clearance (CL) and distribution volume of GS‐441524 were 11.0 L/h (intersubject variability [ISV]% = 43.0%) and 271 L (ISV% = 58.1%), respectively. The CL of GS‐441524 was significantly related to the eGFR (CL × [eGFR/68]<sup>0.745</sup>). The post hoc area under the curve of GS‐441524 was unrelated to the recovery rate or aspartate aminotransferase/alanine aminotransferase elevation. Overall, PopPK analysis showed the rapid elimination of remdesivir in the blood, and GS‐441524 accumulation depended on eGFR in patients with COVID‐19. However, no relevance of exposure–clinical outcome was not suggestive of the dose adjustment of remdesivir.

    DOI: 10.1002/psp4.12936

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/psp4.12936

  8. Evaluating the safety and efficiency of robotic dispensing systems. 査読有り 国際誌

    Tomoki Takase, Norio Masumoto, Naoki Shibatani, Yusaku Matsuoka, Fumiaki Tanaka, Masaki Hirabatake, Hiroko Kashiwagi, Itaru Nishioka, Hiroaki Ikesue, Tohru Hashida, Naoshi Koide, Nobuyuki Muroi

    Journal of pharmaceutical health care and sciences   8 巻 ( 1 ) 頁: 24 - 24   2022年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40780-022-00255-w

    PubMed

  9. Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database. 査読有り 国際誌

    Shiori Hasegawa, Hiroaki Ikesue, Riko Satake, Misaki Inoue, Yu Yoshida, Mizuki Tanaka, Kiyoka Matsumoto, Wataru Wakabayashi, Keita Oura, Nobuyuki Muroi, Tohru Hashida, Kazuhiro Iguchi, Mitsuhiro Nakamura

    Drugs - real world outcomes   9 巻 ( 4 ) 頁: 659 - 665   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s40801-022-00324-4

    PubMed

  10. Population Pharmacokinetics of Nivolumab in Japanese Patients with Non-Small Cell Lung Cancer. 査読有り 国際誌

    Makiko Tohi, Kei Irie, Tomoyuki Mizuno, Hiroyuki Okuyoshi, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Masaaki Eto, Shoji Fukushima, Keisuke Tomii, Tohru Hashida

    Therapeutic drug monitoring     2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/FTD.0000000000000996

    PubMed

  11. Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib 査読有り

    Hiroaki Ikesue, Kenta Yamaoka, Ayako Matsumoto, Masaki Hirabatake, Nobuyuki Muroi, Toshinari Yamasaki, Mutsushi Kawakita, Tohru Hashida

    Cancer Chemotherapy and Pharmacology   89 巻 ( 6 ) 頁: 833 - 838   2022年6月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00280-022-04408-4

    その他リンク: https://link.springer.com/article/10.1007/s00280-022-04408-4/fulltext.html

  12. Association between 25-hydroxyvitamin D levels and COVID-19 severity. 査読有り 国際誌

    Tomoki Takase, Naoko Tsugawa, Takayuki Sugiyama, Hiroaki Ikesue, Masaaki Eto, Tohru Hashida, Keisuke Tomii, Nobuyuki Muroi

    Clinical nutrition ESPEN   49 巻   頁: 256 - 263   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.clnesp.2022.04.003

    PubMed

  13. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib 査読有り

    Hiroaki Ikesue, Haruna Yamamoto, Masaki Hirabatake, Tohru Hashida, Hobyung Chung, Tetsuro Inokuma, Nobuyuki Muroi

    Biological and Pharmaceutical Bulletin   45 巻 ( 3 ) 頁: 333 - 338   2022年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1248/bpb.b21-00913

  14. Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis. 査読有り 国際誌

    Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer   30 巻 ( 3 ) 頁: 2341 - 2348   2022年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: This study evaluated the risk of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer who received denosumab or zoledronic acid (ZA) for treating bone metastasis. METHODS: The medical records of patients were retrospectively reviewed. Patients who did not undergo a dental examination at baseline were excluded. The primary endpoint was a comparison of the risk of developing MRONJ between the denosumab and ZA groups. Propensity score matching was used to control for baseline differences between patient characteristics and compare outcomes for both groups. RESULTS: Among the 799 patients enrolled, 58 (7.3%) developed MRONJ. The incidence of MRONJ was significantly higher in the denosumab group than in the ZA group (9.6% [39/406] vs. 4.8% [19/393], p = 0.009). Multivariate Cox proportional hazards regression analysis revealed that denosumab treatment (hazard ratio [HR], 2.89; 95% confidence interval [CI], 1.65-5.25; p < 0.001) and tooth extraction after starting ZA or denosumab (HR, 4.26; 95% CI, 2.38-7.44; p < 0.001) were significant risk factors for MRONJ. Propensity score-matched analysis confirmed that the risk of developing MRONJ was significantly higher in the denosumab group than in the ZA group (HR, 2.34; 95% CI, 1.17-5.01; p = 0.016). CONCLUSION: The results of this study suggest that denosumab poses a significant risk for developing MRONJ in patients treated for bone metastasis, and thus these patients require close monitoring.

    DOI: 10.1007/s00520-021-06634-7

    PubMed

  15. Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide. 査読有り 国際誌

    Masaki Hirabatake, Hiroaki Ikesue, Yuna Iwama, Kei Irie, Shintaro Yoshino, Toshinari Yamasaki, Tohru Hashida, Mutsushi Kawakita, Nobuyuki Muroi

    Frontiers in pharmacology   13 巻   頁: 901099 - 901099   2022年

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Enzalutamide is useful for the treatment of castration-resistant prostate cancer (CRPC). Despite its usefulness, adverse events (AEs) sometimes force patients to discontinue treatment. To maximize patient care, we developed an ambulatory care pharmacy practice that allows collaboration between a pharmacist and urologist to manage patients with CRPC receiving enzalutamide. In this study, we investigated the efficacy of this collaborative management. Methods: A retrospective chart review of 103 patients with CRPC receiving enzalutamide in our hospital between May 2014 and December 2020 was performed. Our collaborative management was implemented in October 2016. Before being examined by urologists, patients visited the oncology pharmacy consultation room for a face-to-face consultation, wherein the oncology pharmacists assessed factors such as adherence to enzalutamide, any AEs and their grades, and provided their suggestions to the urologists. The time to enzalutamide discontinuation and prostate-specific antigen progression were compared between patients who started enzalutamide before (n = 41) and after (n = 62) the implementation of the collaborative management. A multivariate Cox regression analysis was performed to analyze the factors associated with enzalutamide discontinuation. Results: After implementing collaborative management, the pharmacists had 881 patient consultations. Among the 476 suggestions from pharmacists, 345 were accepted by urologists. The most frequent suggestion was supportive care in enzalutamide treatment (224 suggestions). Multivariate analysis showed that collaborative management [hazard ratio (HR) 0.53, 95% confidence interval (CI) 0.31-0.89, p = 0.017] and higher prostate-specific antigen (PSA; HR 2.41, 95% CI 1.36-4.28, p = 0.003) were significantly associated with enzalutamide discontinuation. The median time to discontinuation (18.9 vs. 7.6 months, p = 0.012), time to discontinuation due to AEs (not reached in both groups, p = 0.001), and time to PSA progression (13.3 vs. 5.8 months, p = 0.002) were all significantly longer in the after group. Conclusions: We implemented a pharmacist-urologist collaborative management program for outpatients with CRPC receiving enzalutamide. The results revealed that collaborative management was useful for prolonging the time to enzalutamide discontinuation.

    DOI: 10.3389/fphar.2022.901099

    PubMed

  16. Population Pharmacokinetics of Favipiravir in Patients with COVID-19. 査読有り

    Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Keisuke Tomii, Tohru Hashida

    CPT: pharmacometrics & systems pharmacology   10 巻 ( 10 ) 頁: 1161 - 1170   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The antiretroviral drug favipiravir inhibits RNA-dependent RNA polymerase. It has been developed for the treatment of novel coronavirus (SARS-CoV-2) infection disease (COVID-19). However, its pharmacokinetics in patients with COVID-19 is poorly understood. In this study, we measured favipiravir serum concentration by liquid chromatography-tandem mass spectrometry and conducted population pharmacokinetic (PPK) analysis. Thirty-nine patients were enrolled in the study: 33 were administered FPV 1600 mg twice-daily (BID) on the first day followed by 600 mg BID, and 6 were administered FPV 1800 mg BID on the first day followed by 800 mg or 600 mg BID. The median age was 68 years (range, 27-89 years), males were 31 (79.5%), median body surface area (BSA) was 1.72 m<sup>2</sup> (range, 1.11-2.2), and patients requiring invasive mechanical ventilation (IMV) at the start of favipiravir was 10 (25.6%). Two-hundred and four serum concentrations were available for pharmacokinetic analysis. A one-compartment model with first-order elimination was used to describe the pharmacokinetics. The estimated mean clearance/bioavailability (CL/F) and distribution volume/bioavailability (V/F) were 5.11 L/h and 41.6 L, respectively. Covariate analysis revealed that CL/F was significantly related to dosage, IMV use, and BSA. Simulation study showed that the 1600 mg/600 mg BID regimen was insufficient for the treatment of COVID-19 targeting EC50 (9.7µg/mL), especially in patients with larger BSA and/or IMV. A higher favipiravir dosage is required for COVID-19, but dose-dependent nonlinear pharmacokinetics may cause an unexpected significant pharmacokinetic change and drug toxicity. Further studies are warranted to explore the optimal favipiravir regimen.

    DOI: 10.1002/psp4.12685

    PubMed

  17. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study. 査読有り

    Kanae Yamashita, Yoshimitsu Shimomura, Hiroaki Ikesue, Nobuyuki Muroi, Akihiro Yoshimoto, Tohru Hashida

    BMC infectious diseases   21 巻 ( 1 ) 頁: 664   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    <h4>Background</h4>Pneumocystis pneumonia (PCP) is a potentially life-threatening infection. Trimethoprim-sulfamethoxazole (TMP-SMX) is considered as the first regimen for PCP prophylaxis according to several guidelines. The recommended prophylactic dose of TMP-SMX has been determined based on patients with normal renal function, but the appropriate dosage for patients undergoing hemodialysis is unknown. The aim of this study was to investigate the efficacy and safety of low-dose TMP-SMX in patients undergoing hemodialysis.<h4>Methods</h4>HIV-uninfected adult patients who were undergoing hemodialysis and administered TMP-SMX for PCP prophylaxis, were included, and divided into standard-dose (≥6 single strength (SS, TMP-SMX 80 mg/400 mg tablets/week) and low-dose groups (< 6 SS tablets/week). The endpoints were cumulative incidence of PCP and cumulative discontinuation rate of TMP-SMX due to adverse events. For comparison of the groups, we employed the chi-squared test for categorical variables and the Mann-Whitney U test for continuous variables. Risk factors for the endpoints were evaluated using the Cox Fine and Gray method.<h4>Results</h4>The median age of the 81 patients included in the study was 67 years (IQR: 60-76 years), and 52 patients (64.2%) were men. No patients in either group developed PCP during the observation period. The yearly cumulative incidence of discontinuation was 12.1% (95% confidence interval [CI]: 0.027-0.29) in the low-dose group and 35.6% (95% CI: 0.20-0.52) in the standard-dose group (P = 0.019). The adjusted hazard ratio of the low-dose group compared to standard-dose group was 0.18 (95% CI: 0.04-0.86, P = 0.032).<h4>Conclusions</h4>None of the study patients developed PCP, and the cumulative discontinuation rate of TMP-SMX due to adverse events was significantly lower in the low-dose group compared to that in the standard-dose group (P = 0.032). These results indicate that low-dose TMP-SMX is an appropriate regimen to maintain a balance between PCP prophylaxis and prevention of adverse events due to TMP-SMX administration. These findings can guide health care professionals to determine TMP-SMX dosage when considering PCP prophylaxis for patients undergoing hemodialysis.

    DOI: 10.1186/s12879-021-06374-3

    PubMed

  18. Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database. 査読有り

    Misaki Inoue, Kiyoka Matsumoto, Mizuki Tanaka, Yu Yoshida, Riko Satake, Fumiya Goto, Kazuyo Shimada, Ririka Mukai, Shiori Hasegawa, Takaaki Suzuki, Hiroaki Ikesue, Jun Liao, Tohru Hashida, Mitsuhiro Nakamura

    Scientific reports   11 巻 ( 1 ) 頁: 11324   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media LLC  

    Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse event associated with several antineoplastic drugs; however, the precise risks and time course of reactions of particular drugs are not clearly understood. The aim of this study was to evaluate the relationship between anticancer agents and CIPN development using data from the Japanese Adverse Drug Event Report (JADER) database and to characterize the time-to-onset and outcomes of CIPN. Chemotherapy-induced peripheral neuropathy was defined using the Medical Dictionary for Regulatory Activities preferred terms. Disproportionality analysis was performed by calculating the reporting odds ratio (ROR) with 95% confidence interval for signal detection. Data of nine Anatomical Therapeutic Chemical (ATC) drug categories correlated with CIPN development, in addition to the data of the time-to-onset and outcomes. Among 622,289 reports in the JADER database from April 2004 to March 2020, there were 1883 reports of adverse events corresponding to peripheral neuropathy. The ROR (95% confidence interval) for vinblastine, sorbent-based paclitaxel (sb-PTX), oxaliplatin, and bortezomib was 20.4 (12.5-33.4), 13.6 (11.9-15.7), 26.2 (23.6-29.1), and 30.8 (26.6-35.8), respectively. The median duration (interquartile range) to CIPN development after the administration of vinca alkaloids and analogues, taxanes, platinum compounds, and monoclonal antibodies was 11.0 (5.0-46.5), 22.5 (6.0-82.5), 22.0 (6.0-68.5), and 32.5 (11.3-73.8) days, respectively. The median duration (interquartile range) of sb-PTX and nanoparticle albumin-bound (nab)-PTX was 35.0 (7.0-94.0) and 5.5 (3.0-29.3) days, respectively. Our analysis of records in the JADER database revealed several drugs associated with a high risk for CIPN development. In particular, the development of CIPN after vinca alkaloid administration should be closely monitored for 2 weeks after administration. CIPN caused by nab-PTX showed significantly faster onset than that by sb-PTX. Patients who receive taxanes or monoclonal antibodies often do not show an improvement; accordingly, early treatment is required.

    DOI: 10.1038/s41598-021-90848-6

    PubMed

  19. Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting. 査読有り

    Fumiaki Tanaka, Naoki Shibatani, Kazumi Fujita, Hiroaki Ikesue, Satoru Yoshimizu, Nobuyuki Muroi, Yasuo Kurimoto, Tohru Hashida

    J Pharm Health Care Sci   7 巻 ( 1 ) 頁: 17   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40780-021-00196-w

    PubMed

  20. Safety evaluation of enzalutamide dose-escalation strategy in patients with castration-resistant prostate cancer 査読有り

    Rieko Miura, Masaki Hirabatake, Kei Irie, Hiroaki Ikesue, Nobuyuki Muroi, Mutsushi Kawakita, Tohru Hashida

    Urologic Oncology: Seminars and Original Investigations   39 巻 ( 4 ) 頁: 233.e15 - 233.e20   2021年4月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier BV  

    DOI: 10.1016/j.urolonc.2020.09.013

    PubMed

  21. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. 査読有り 国際誌

    Hiroaki Ikesue, Kohei Doi, Mayu Morimoto, Masaki Hirabatake, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Tohru Hashida

    Cancer chemotherapy and pharmacology   87 巻 ( 6 ) 頁: 871 - 877   2021年3月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00280-021-04262-w

    PubMed

  22. Population pharmacokinetics of tacrolimus in umbilical cord blood transplant patients focusing on the variation in red blood cell counts 査読有り 国際誌

    Saki Yoshida, Ayumi Fujimoto, Keizo Fukushima, Motozumi Ando, Kei Irie, Tatsuya Hirano, Moena Miyasaka, Yoshimitsu Shimomura, Takayuki Ishikawa, Hiroaki Ikesue, Nobuyuki Muroi, Tohru Hashida, Nobuyuki Sugioka

    Journal of Clinical Pharmacy and Therapeutics   46 巻 ( 1 ) 頁: 190 - 197   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/jcpt.13279

    PubMed

  23. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases 査読有り 国際誌

    Hiroaki Ikesue, Moe Mouri, Hideaki Tomita, Masaki Hirabatake, Mai Ikemura, Nobuyuki Muroi, Shinsuke Yamamoto, Toshihiko Takenobu, Keisuke Tomii, Mutsushi Kawakita, Hironori Katoh, Takayuki Ishikawa, Hisateru Yasui, Tohru Hashida

    Support Care Cancer   29 巻 ( 8 ) 頁: 4763 - 4772   2021年2月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00520-021-06018-x

    PubMed

  24. Analysis of Drug-Induced Gastrointestinal Obstruction and Perforation Using the Japanese Adverse Drug Event Report Database. 査読有り 国際誌

    Riko Satake, Kiyoka Matsumoto, Mizuki Tanaka, Ririka Mukai, Kazuyo Shimada, Yu Yoshida, Misaki Inoue, Shiori Hasegawa, Kazuhiro Iguchi, Hiroaki Ikesue, Shinya Shimizu, Shohei Nishida, Akio Suzuki, Tohru Hashida, Mitsuhiro Nakamura

    Frontiers in pharmacology   12 巻   頁: 692292 - 692292   2021年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Drug-induced gastrointestinal obstruction (DIGO) and gastrointestinal perforation (DIGP) may be the result of gastrointestinal hypomotility and severe constipation, which may lead to potentially fatal complications of bowel ischemia, sepsis and perforation. We evaluated the onset profile of DIGs (DIGO and DIGP) associated with prescription drugs by analyzing data in the Japanese Adverse Drug Event Report (JADER) database. We selected 161 DIG-related drugs and categorized them into 19 classes based on the Anatomical Therapeutic Chemical (ATC) Classification System. Finally, we focused on 58 drugs and conducted subsequent analyses for the time-to-onset and outcomes. We extracted 79 preferred terms (PTs) with the strings "ileus," "stenosis," "obstruction," "obstructive," "impaction," "perforation," "perforated," "hypomotility," and "intussusception" from the Standardized Medical Dictionary for Regulatory Activities (MedDRA) Queries (SMQs) of SMQ20000104: gastrointestinal perforation, ulcer, hemorrhage, obstruction non-specific findings/procedures; SMQ20000105: gastrointestinal obstruction; and SMQ20000107: gastrointestinal perforation. Among the 667, 729 reports in the JADER database submitted between April 2004 and November 2020, we identified 11,351 occurrences of DIGs. The reporting odds ratios (RORs) (95% confidence interval) of "barium sulfate containing X-ray media," "drugs for treatment of hyperkalemia and hyperphosphatemia," and "oral bowel cleanser" were 142.0 (127.1-158.6), 25.8 (23.1-28.8), and 29.7 (24.8-35.6), respectively. The median number of days (interquartile range) until the onset of an adverse event caused by each drug category was as follows: barium sulfate containing X-ray contrast media [2.0 (1.0-3.0)], diazepines, oxazepines, thiazepines, and oxepines [8.0 (8.0-18.5)], drugs for treatment of hyperkalemia and hyperphosphatemia [29.0 (8.0-55.0)], non-selective monoamine reuptake inhibitors [19.0 (7.0-47.5)], and oral bowel cleanser [0.0 (0.0-0.0)]. Depending on the drug, the time to onset of side effects ranged from days to several months. Our results highlighted the need to perform detailed monitoring of each drug for possible association with DIGs, which might otherwise have fatal consequences.

    DOI: 10.3389/fphar.2021.692292

    PubMed

  25. Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer 査読有り 国際誌

    Hiroaki Ikesue, Kaori Kusuda, Yukari Satsuma, Fuki Nishiwaki, Rieko Miura, Yoshio Masuda, Masaki Hirabatake, Nobuyuki Muroi, Daichi Fujimoto, Takeshi Morimoto, Keisuke Tomii, Tohru Hashida

    Journal of Clinical Pharmacy and Therapeutics   45 巻 ( 6 ) 頁: 1288 - 1294   2020年12月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/jcpt.13207

    PubMed

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/jcpt.13207

  26. Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone 査読有り

    Yukari Satsuma, Hiroaki Ikesue, Kaori Kusuda, Mami Maeda, Nobuyuki Muroi, Ryobu Mori, Mariko Kogo, Ryosuke Hirabayashi, Kazuma Nagata, Atsushi Nakagawa, Ryo Tachikawa, Keisuke Tomii, Tohru Hashida

    Frontiers in Pharmacology   11 巻   頁: 529654   2020年11月

     詳細を見る

    担当区分:責任著者   掲載種別:研究論文(学術雑誌)   出版者・発行元:Frontiers Media {SA}  

    <jats:p><jats:bold>Background:</jats:bold> Pirfenidone is an anti-fibrotic agent used to treat patients with idiopathic pulmonary fibrosis (IPF). Managing adverse drug events and ensuring compliance with pirfenidone treatment for a prolonged period are important to reduce the rate of disease progression. To maximize the benefits of pirfenidone treatment, we established and evaluated an ambulatory care pharmacy practice, a model of pharmacist–physician collaborative management, for patients receiving pirfenidone.</jats:p><jats:p><jats:bold>Methods:</jats:bold> We conducted a retrospective chart review of 76 consecutive patients treated with pirfenidone in the Kobe City Medical Center General Hospital, Japan, between January 2012 and January 2019. The first group (61 patients) received pirfenidone treatment as conventional management, whereas the second group (15 patients) started pirfenidone based on collaborative pharmacist–physician management. The drug discontinuation rate and time to drug discontinuation were compared between the groups. To analyze factors associated with pirfenidone discontinuation, we used a multivariate Cox regression analysis to evaluate the baseline characteristics of patients, including those receiving the collaborative management. Clinical outcomes were compared using a propensity score matched analysis.</jats:p><jats:p><jats:bold>Results:</jats:bold> In the collaborative management group, pharmacists made 56 suggestions, including suggestions for supportive care (51 suggestions), to the physicians. Among these suggestions, 52 were accepted by the physicians. The discontinuation rates at 3 [6.7% (1/15) vs. 26.2% (16/61)] and 6 [9.1% (1/11) vs. 36.1% (22/61)] months were lower in the collaborative management group than in the conventional management group. Multivariate analysis revealed that collaborative management [hazard ratio (HR) 0.34, 95% CI 0.08–0.96, <jats:italic>p</jats:italic> = 0.041] and predicted baseline forced vital capacity &amp;lt;60% (HR 2.13, 95% CI 1.17–3.85, <jats:italic>p</jats:italic> = 0.015) were significantly associated with pirfenidone discontinuation. The time to drug discontinuation was also significantly longer in the collaborative management group than in the conventional management group (<jats:italic>p</jats:italic> = 0.034, log-rank test). Propensity score matched analysis confirmed a significant correlation between collaborative management and drug discontinuation time (HR 0.20, 95% CI 0.03–0.84, <jats:italic>p</jats:italic> = 0.027).</jats:p><jats:p><jats:bold>Conclusions:</jats:bold> We established an ambulatory care pharmacy practice for out-patients with IPF receiving pirfenidone. The results suggest that collaborative management may help prevent pirfenidone discontinuation compared with conventional management.</jats:p>

    DOI: 10.3389/fphar.2020.529654

  27. Assessment of Reye’s syndrome profile with data from the US Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis 査読有り 国際誌

    Kiyoka Matsumoto, Shiori Hasegawa, Satoshi Nakao, Kazuyo Shimada, Ririka Mukai, Mizuki Tanaka, Riko Satake, Yu Yoshida, Fumiya Goto, Misaki Inoue, Hiroaki Ikesue, Kazuhiro Iguchi, Tohru Hashida, Mitsuhiro Nakamura

    SAGE open medicine   8 巻   頁: 2050312120974176   2020年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1177/2050312120974176

    PubMed

  28. Risk Factors for Skin Toxicities Associated with Bendamustine-Based Chemotherapy in Patients with Non-Hodgkin Lymphoma 査読有り

    Mayako Uchida, Yasuhiro Mori, Kenta Akiba, Moena Miyasaka, Tatsuya Hirano, Hiroaki Ikesue, Yuki Yamaguchi, Aoi Takano, Nami Maegawa, Yoshimitsu Shimomura, Keiko Hosohata, Nobuyuki Muroi, Takayuki Ishikawa, Tohru Hashida, Tsutomu Nakamura

    Biological and Pharmaceutical Bulletin   43 巻 ( 10 ) 頁: 1577 - 1582   2020年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1248/bpb.b20-00428

    PubMed

  29. Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19 査読有り

    Kei Irie, Atsushi Nakagawa, Hirotoshi Fujita, Ryo Tamura, Masaaki Eto, Hiroaki Ikesue, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida

    Clinical and Translational Science   13 巻 ( 5 ) 頁: 880 - 885   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/cts.12827

    PubMed

    その他リンク: https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cts.12827

  30. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. 査読有り 国際誌

    Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M

    Pharmacoepidemiology and drug safety   29 巻 ( 10 ) 頁: 1279 - 1294   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE:The aim of our study was to characterize the clinical features of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) in a real-world setting using the Japanese Adverse Drug Event Report (JADER) database. METHODS:The irAEs were defined using the preferred terms of the Medical Dictionary for Regulatory Activities. irAEs were categorized as follows: adrenal insufficiency, colitis, eye diseases, hematological disorder, hepatitis, hyperthyroidism, hypopituitarism, hypothyroidism, myasthenia gravis, myocarditis, nephritis/renal dysfunction, pneumonitis, rash, and type 1 diabetes mellitus. We used several indices such as reporting odds ratio (ROR) to assess disproportionality in pharmacovigilance data, time-to-onset analysis using Weibull shape parameters, and the association rule mining technique to evaluate possible risk factors between variables in the spontaneous reporting system database. RESULTS:The JADER database contained 534 688 reports from April 2004 to June 2018. The RORs of pneumonitis including interstitial lung disease for nivolumab, pembrolizumab, and ipilimumab were 7.02 (95% confidence interval: 6.55-7.52), 9.08 (8.28-9.97), and 1.74 (1.27-2.38), respectively. The median onsets (quartiles, 25-75%) of myocarditis caused by nivolumab and pembrolizumab were 28.0 (15.5-60.5) and 18.0 (13.0-44.5) days, respectively. Co-therapy with nivolumab and ipilimumab may be associated with irAEs in several categories as per the association rule mining analysis. CONCLUSION:Our results demonstrated a potential risk of irAEs associated with ICIs, based on RORs and time-to-onset analysis. Furthermore, our findings indicated that patients receiving nivolumab and ipilimumab as co-therapy should be carefully monitored.

    DOI: 10.1002/pds.5108

    PubMed

  31. Risk Factors for Febrile Neutropenia Induced by Docetaxel Chemotherapy in Patients with Non-small Cell Lung Cancer. 査読有り

    Mayako Uchida, Yuki Yamaguchi, Syuhei Hosomi, Hiroaki Ikesue, Yasuhiro Mori, Nami Maegawa, Aoi Takano, Yuki Sato, Keiko Hosohata, Nobuyuki Muroi, Keisuke Tomii, Tohru Hashida, Tsutomu Nakamura

    Biological & Pharmaceutical Bulletin   43 巻 ( 8 ) 頁: 1235 - 1240   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1248/bpb.b20-00266

    PubMed

  32. Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban. 査読有り

    Tomoki Takase, Hiroaki Ikesue, Haruna Nakagawa, Megumi Kinoshita, Nobuyuki Muroi, Takeshi Kitai, Yutaka Furukawa, Tohru Hashida

    Journal of Clinical Pharmacy and Therapeutics   45 巻 ( 2 ) 頁: 298 - 302   2020年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/jcpt.13065

    PubMed

  33. Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database. 査読有り 国際誌

    Satoshi Nakao, Shiori Hasegawa, Kazuyo Shimada, Ririka Mukai, Mizuki Tanaka, Kiyoka Matsumoto, Hiroaki Uranishi, Mayuko Masuta, Hiroaki Ikesue, Tohru Hashida, Kazuhiro Iguchi, Mitsuhiro Nakamura

    Int J Med Sci   17 巻 ( 7 ) 頁: 921 - 930   2020年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.7150/ijms.43789

    PubMed

  34. Association of Hypnotic Drug Use with Fall Incidents in Hospitalized Elderly Patients: A Case-Crossover Study. 査読有り

    Haruki Torii, Motozumi Ando, Hideaki Tomita, Tomoko Kobaru, Mahoko Tanaka, Kazuhide Fujimoto, Rumiko Shimizu, Hiroaki Ikesue, Satoshi Okusada, Tohru Hashida, Noriaki Kume

    Biological and Pharmaceutical Bulletin   43 巻 ( 6 ) 頁: 925 - 931   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1248/bpb.b19-00684

    PubMed

  35. Risk factors for major bleeding and clinically relevant non-major bleeding in Japanese patients treated with edoxaban. 査読有り

    Tomoki Takase 1, Hiroaki Ikesue 1, Haruna Nakagawa 1, Megumi Kinoshita 1, Nobuyuki Muroi 1, Takeshi Kitai 2, Yutaka Furukawa 2, Tohru Hashida 1   43 巻 ( 3 ) 頁: 458 - 462   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1248/bpb.b19-00799

    PubMed

  36. A case of acute kidney injury associated with dabrafenib and trametinib treatment for metastatic melanoma 査読有り

    Hiroaki Ikesue, Tohru Nagano, Tohru Hashida

    Ann Pharmacother   52 巻 ( 10 ) 頁: 1051 - 1052   2018年10月

     詳細を見る

    担当区分:筆頭著者, 責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PubMed

  37. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis 査読有り

    Haruna Yamamoto, Hiroaki Ikesue, Mai Ikemura, Rieko Miura, Kazumi Fujita, Hobyung Chung, Yoshiki Suginoshita, Tetsuro Inokuma, Tohru Hashida

    Journal of Pharmaceutical Health Care and Sciences   4 巻   頁: 17   2018年7月

     詳細を見る

    担当区分:責任著者   記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1186/s40780-018-0113-3

  38. Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery.

    Hiroaki Ikesue

    Journal of Pharmaceutical Health Care and Sciences     2018年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  39. Comparison of antiemetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy.

    Hiroaki Ikesue

    Pharmazie     2018年5月

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  40. Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation

    Hiroaki Ikesue

    Int J Hematol   105 巻 ( 3 ) 頁: 361 - 368   2017年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The aim of this retrospective study was to identify variable factors affecting tacrolimus blood concentration during the switch from continuous intravenous infusion to twice-daily oral administration in allogeneic hematopoietic stem cell transplant recipients (n = 73). The blood concentration/dose ratio of tacrolimus immediately before the change from continuous infusion (C/Div) was compared with that between 3 and 5 days after the change to oral administration (C/Dpo). Median (C/Dpo)/(C/Div) was 0.21 (range 0.04-0.58). Multiple regression analysis showed that concomitant use of oral itraconazole or voriconazole significantly increased the (C/Dpo)/(C/Div) of tacrolimus (p = 0.002), probably owing to the inhibition of enterohepatic cytochrome P450 3A4. In addition, 5 of 18 (28%) patients who had the lowest quartile (C/Dpo)/(C/Div) values developed acute graft-versus-host-disease (GVHD), which was significantly higher than in others [5 of 55 (9%) patients, p = 0.045]. Although the switch from intravenous to oral administration at a ratio of 1:5 appeared to be appropriate, a lower conversion ratio was suitable in patients taking oral itraconazole or voriconazole. In patients whose blood concentration decreases after the switch, the development of GVHD should be monitored and tacrolimus dosage should be readjusted to maintain an appropriate blood concentration.

    DOI: 10.1007/s12185-016-2135-7

    PubMed

  41. 集中治療室における注射剤配合変化早見表の作成と有用性の評価

    石田 茂, 武田 真樹, 尾川 理恵, 中島 貴史, 池末 裕明, 渡邊 裕之, 金谷 朗子, 江頭 伸昭, 増田 智先

    医療薬学   42 巻 ( 4 ) 頁: 286 - 294   2016年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本医療薬学会  

    集中治療室における注射剤配合変化早見表の作成と有用性について検討した。ICUにおける6ヵ月間の注射剤使用実績を基に、主に持続静注され、薬剤師が特に日常診療で使用頻度が高いと判断した注射剤35品目を対象とした。作成した配合変化早見表において、薬剤名(商品名)は薬効別に表記することで、日常診療で実際に配合されやすい薬剤同士が近傍に配置されるよう工夫した。規格pHならびに製剤学的特徴については、十分な根拠資料がない場合において配合可否の推測に有用であるため、それぞれ薬剤名の右列に掲載した。製剤学的特徴の右列には薬剤毎にアルファベットを付し、行列のアルファベットを交差させることで配合可否の記号を確認できる形式とした。配合変化早見表の有用性は、「とても有用」または「やや有用」と評価した対象者の割合は、看護師では合計86.9%、医師では合計100%であった。配合変化早見表の運用により、調査時間は運用前と比較し運用後で有意に短縮した。相談に対する調査時間も配合変化早見表の運用前と比較し運用後で有意に短縮した。

    DOI: 10.5649/jjphcs.42.286

  42. エルロチニブおよびゲフィチニブ服薬患者の理解度向上のための患者教育体制の構築とその評価

    三牧 沙織, 渡邊 裕之, 永田 健一郎, 池末 裕明, 山本 千鶴子, 道下 真里子, 辻川 智子, 平野 めぐみ, 渡部 仁美, 天尾 カオル, 江頭 伸昭, 岩間 映二, 高山 浩一, 増田 智先

    医療薬学   41 巻 ( 8 ) 頁: 566 - 577   2015年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本医療薬学会  

    実施している患者教育の有用性について、エルロチニブおよびゲフィチニブ導入初期および退院時における患者理解度を比較評価した。解析対象は39名(男性20名、女性19名、年齢中央値67歳)で、服薬歴はエルロチニブ1名、ゲフィチニブ7名であった。正答率は65歳以上で導入時76.2、退院時95.2、65歳未満で導入時71.4、退院時95.2とそれぞれ有意に改善した。服薬歴の有無によるエルロチニブ、ゲフィチニブ導入時、退院時の理解度に差は認めなかった。

  43. Risk factors for predicting severe neutropenia induced by pemetrexed plus carboplatin therapy in patients with advanced non-small cell lung cancer.

    Hiroaki Ikesue

    Biol Pharm Bull   38 巻 ( 8 ) 頁: 1192 - 8   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pemetrexed plus carboplatin therapy is widely administered to patients with non-squamous non-small cell lung cancer. Although severe neutropenia is often observed during this combination therapy, its predictive factors are unknown. Therefore, we investigated the predictive factors for severe neutropenia in 77 patients treated with this combination therapy at the Department of Respiratory Medicine, Kyushu University Hospital, between September 2009 and September 2013. All data were retrospectively collected from the electronic medical record system, and univariate and multivariate logistic regression analyses were performed to identify risk factors for grade 3 or 4 neutropenia. Among the 77 patients, 34 (44%) developed grade 3 or 4 neutropenia. Multivariate analysis revealed that lower baseline hemoglobin values (odds ratio [OR], 1.97 per 1 g/dL decrease; 95% confidence interval [CI], 1.39-2.99, p<0.01) and lower baseline neutrophil counts (OR, 1.71 per 1000/mm(3) decrease; 95% CI, 1.14-2.71, p=0.01) were significantly associated with grade 3 or 4 neutropenia. During 4 courses of pemetrexed plus carboplatin therapy, the incidence of grade 3 or 4 neutropenia in patients with baseline hemoglobin values of <11.6 g/dL was significantly higher than that in patients with values of ≥11.6 g/dL [84% (16/19) vs. 31% (18/58), p<0.001]. In conclusion, patients with lower baseline neutrophil counts or lower baseline hemoglobin values, especially those with baseline hemoglobin values of <11.6 g/dL, should be monitored more carefully during pemetrexed plus carboplatin therapy.

    DOI: 10.1248/bpb.b15-00162

    PubMed

  44. Differences in recognition of similar medication names between pharmacists and nurses: a retrospective study 国際誌

    Hiroaki Ikesue

    J Pharm Health Care Sci   1 巻   頁: 19 - 19   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Differences in error rates between pharmacists and nurses in terms of drug confirmation have not been studied. The purpose of this study was to analyze differences in error rates between pharmacists and nurses from the viewpoint of error categories, and to clarify differences in recognition regarding drug name similarity. METHODS: In this study, preparation errors and incidents were classified into three categories (drug strength errors, drug name errors, and drug count errors) to investigate the influence of error categories on pharmacists and nurses. In addition, errors in two categories (drug strength errors and drug name errors) were reclassified into another two error groups, to investigate the influence of drug name similarity on pharmacists and nurses: a "drug name similarity (-) group" and a "drug name similarity (+) group". Then, differences in error rates of pharmacists and those of nurses were analyzed respectively within three categories and two groups. Furthermore, differences in error rates between pharmacists and nurses were analyzed in each of the three categories and two groups. RESULTS: Error rates of pharmacists for both drug strength errors and drug name errors were significantly higher than that for drug count errors, and similar results were obtained for nurses (P < 0.05). However, there were no significant differences in error rates between pharmacists and nurses in each of the three categories. Furthermore, error rate of nurses was significantly higher than that of pharmacists in the drug name similarity (+) group (P < 0.05), while there was no significant difference in error rates between pharmacists and nurses in the drug name similarity (-) group. CONCLUSIONS: These results suggest that in contrast to pharmacists, nurses are easily affected by similarities in drug names. Therefore, pharmacists should offer information on medications having plural strengths or similar names to nurses, in order to minimize damage to patients resulting from errors.

    DOI: 10.1186/s40780-015-0017-4

    PubMed

  45. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer 国際誌

    Hiroaki Ikesue

    Ann Pharmacother   48 巻 ( 9 ) 頁: 1159 - 1165   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Severe hypocalcemia sometimes develops during denosumab treatment for bone metastases from cancer and is, therefore, an important issue. However, limited information is available on the risk factors for hypocalcemia and the appropriate interval for monitoring serum calcium concentration. OBJECTIVE: The present study aimed to identify the risk factors for grade ≥2 hypocalcemia and to investigate the time course of serum calcium concentrations in patients receiving denosumab for bone metastases from cancer. METHOD: The medical records of 66 cancer patients treated with denosumab between April 2012 and August 2013 were retrospectively reviewed. RESULT: Of the 66 enrolled patients, 11, 5, and 1 developed grade 1, 2, and 3 hypocalcemia, respectively. All 4 patients with a baseline estimated glomerular filtration rate (eGFR) of <30 mL/min developed hypocalcemia. Hypocalcemia occurred in only 20%, 24%, and 15% of patients with an eGFR of 30 to 59, 60 to 89, and ≥90 mL/min, respectively. Multivariate logistic regression analysis revealed that lower eGFR values (odds ratio, 1.72 per 10 mL/min decrease, P = 0.02) were significantly associated with grade ≥2 hypocalcemia. In 11 patients who developed hypocalcemia during the first treatment course, the mean calcium concentrations decreased from 9.8 mg/dL at baseline to 8.4 mg/dL during the first week and reached a nadir of 8.1 mg/dL during the second week. CONCLUSION: Our results support more frequent monitoring of serum calcium concentrations at baseline and during the first 2 weeks of treatment in patients receiving denosumab, especially those with an eGFR <30 mL/min.

    PubMed

  46. 精神科薬物療法モニタリングシステムの構築と評価

    永田 健一郎, 江頭 伸昭, 池末 裕明, 渡邊 裕之, 大石 了三

    日本病院薬剤師会雑誌   49 巻 ( 3 ) 頁: 261 - 265   2013年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    精神科チーム医療では、薬剤師が薬物療法に関する情報を収集・管理し、処方の妥当性を評価することによって、医師の処方設計を支援することが求められる。しかしながら実臨床では、マンパワーの不足により十分な薬学的関与を行うことが困難な状況である。そこで我々は、情報管理と処方評価の効率化および標準化を目的として、精神科薬物療法のモニタリングに有用なシステムを構築した。市販のデータベースソフトを用いて、向精神薬140品目の薬剤情報を登録し、患者情報および処方情報を入力した。本システムの導入により、患者情報および処方情報の管理に要する時間が有意に短縮した。さらに、本システムを活用し、薬物療法モニタリングシートおよび薬歴情報シートを作成することによって、処方提案を円滑に行うことが可能となった。以上のことから、本システムは、精神科病棟薬剤師業務の効率化および標準化に有用と考えられた。(著者抄録)

  47. 精神科薬物療法の効率的なモニタリングを目的としたシステムの構築と評価

    永田 健一郎, 有村 洋平, 渡邊 裕之, 池末 裕明, 江頭 伸昭, 大石 了三

    日本薬学会年会要旨集   133年会 巻 ( 4 ) 頁: 209 - 209   2013年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本薬学会  

  48. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation 国際誌

    Hiroaki Ikesue

    Pharmacotherapy   33 巻 ( 9 ) 頁: 893 - 901   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    STUDY OBJECTIVE: To evaluate the efficacy and safety of aprepitant added to standard antiemetic regimens used in high-dose chemotherapy for allogeneic hematopoietic stem cell transplantation (allo-HSCT). DESIGN: Retrospective medical record review. SETTING: Hematology ward of a university hospital in Japan. PATIENTS: Of 88 patients treated with high-dose chemotherapy followed by allo-HSCT, 46 received aprepitant and granisetron as antiemetic therapy (between April 1, 2010, and December 31, 2011), and 42 received granisetron alone (between April 1, 2008, and March 31, 2010). INTERVENTIONS: Patients in both groups received 3 mg of granisetron intravenously 30 minutes before the administration of anticancer drugs. In the aprepitant group, 125 mg of aprepitant was administered orally 60-90 minutes before the administration of the first moderately to highly emetogenic anticancer drug. On the following days, 80 mg of aprepitant was administered orally every morning. The mean administration duration of aprepitant was 3.3 days (range 3-6 days). MEASUREMENTS AND MAIN RESULTS: The primary objective was to evaluate the percentage of patients who achieved complete response (CR; no vomiting and none to mild nausea). The CR rate in the aprepitant group was significantly higher than that in the control group (48% vs 24%, p=0.02). Multivariate analysis showed that nonprophylactic use of aprepitant was associated with failure to achieve CR (odds ratio [OR] 2.92; 95% confidence interval [CI] 1.13-7.99, p=0.03). The frequency of abdominal pain was lower in the aprepitant group (9% vs 25%, p=0.03). Rates of other frequently observed adverse drug events were similar between groups. There was no significant difference in neutrophil engraftment (median 18 vs 17 days), platelet engraftment (median 32 vs 32 days), the incidence of acute graft-versus-host-disease (63% vs 55%, p=0.52), viral infection (74% vs 67%, p=0.49), or 1-year overall survival (63% vs 62%, p=0.90) between the two groups. CONCLUSIONS: The addition of aprepitant to granisetron increases the antiemetic effect without influencing transplantation-related toxicities in allo-HSCT.

    DOI: 10.1002/phar.1294

    PubMed

  49. Decrease in venous irritation by adjusting the concentration of injected bendamustine

    Hiroaki Ikesue

    Biol Pharm Bull   36 巻 ( 4 ) 頁: 574 - 8   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Intravenous injection of bendamustine often causes venous irritation and also deteriorates the patient's quality of life. Thus, we evaluated the risk factors associated with venous irritation induced by bendamustine in patients with follicular lymphoma or mantle cell lymphoma. We also evaluated the effectiveness of intervention of changing the preparation procedure for bendamustine. All data were retrospectively collected from the electronic medical record system. In the initial analysis of the total 43 courses of bendamustine therapy, most patients (88%) were administered bendamustine with 250 mL of diluent according to the bendamustine package insert in Japan. The median concentration of bendamustine solution (0.56 mg/mL vs. 0.24 mg/mL) and the incidences of venous irritation (66% vs. 0%, p=0.01) were significantly different between the patients receiving bendamustine at 250 mL and 500 mL of diluent. Based on this result, we proposed changing the final volume of bendamustine dissolution from 250 to 500 mL, which is recommended in other countries. After this intervention, the incidence of venous irritation was significantly reduced from 58 to 20% (p=0.02). The incidence of venous irritation increased in a concentration-dependent manner (≤0.40 mg/mL: 6%; 0.41-0.60 mg/mL: 62%, p<0.001; >0.60 mg/mL: 75%, p<0.001). We conclude that a high concentration bendamustine solution is a risk factor for venous irritation and that 500 mL of diluent is ideal. To further reduce the incidence of venous irritation, the concentration of bendamustine solution is recommended to be 0.40 mg/mL or less.

    PubMed

  50. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation

    Hiroaki Ikesue

    Biol Pharm Bull   36 巻 ( 5 ) 頁: 819 - 24   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    For patients receiving high-dose chemotherapy, a 5-hydroxytryptamine 3 receptor antagonist combined with dexamethasone is a standard antiemetic therapy. Despite this prophylactic anti-emetic treatment, many patients still suffer from uncontrollable emesis. In this study, we retrospectively evaluated the antiemetic effectiveness and safety of aprepitant (a neurokinin-1 receptor antagonist) in addition to 5-HT3 antagonist in Japanese patients with hematologic malignancy receiving high-dose chemotherapy prior to autologous peripheral blood stem cell transplantation (auto-PBSCT). Twenty-six patients received aprepitant and granisetron (the aprepitant group), whereas, 22 patients received granisetron alone (the control group). All patients received 3 mg of granisetron intravenously 30 min before chemotherapy administration. Patients in the aprepitant group additionally received 125 mg of aprepitant 60-90 min before administration of the first moderately to highly emetogenic chemotherapy. On the next day or thereafter, 80 mg of aprepitant was administered in the morning until the last administration of moderately to highly emetogenic anticancer drugs. The percentage of patients who achieved complete response (CR), defined as no emesis with only grade 1-2 nausea, in the aprepitant group was significantly higher than that in the control group (42% vs. 5%, p=0.003). Logistic regression analysis showed that non-prophylactic use of aprepitant was significantly associated with non-CR. The frequencies of adverse drug events (ADEs) were not significantly different between two groups. In conclusion, the results of this study suggest that the addition of aprepitant to granisetron can improve the antiemetic effect without increasing ADEs in patients receiving high-dose chemotherapy prior to auto-PBSCT.

    PubMed

  51. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy 国際誌

    Hiroaki Ikesue

    Am J Health Syst Pharm   70 巻 ( 4 ) 頁: 343 - 9   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. METHODS: All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All patients received 3 mg of granisetron i.v. 30 minutes before chemotherapy administration. Patients in the aprepitant group received 125 mg of aprepitant orally 60-90 minutes before administration of the first moderately to highly emetogenic chemotherapy (day 1). On day 2 or thereafter, an 80-mg oral dose of aprepitant was administered in the morning for up to five days. The primary endpoint was the percentage of patients who achieved complete response (CR). RESULTS: A total of 42 patients were treated with aprepitant and granisetron as antiemetic prophylaxis between April and December 2010 (aprepitant group), and 40 patients were treated with only granisetron between March 1, 2009, and March 31, 2010, before the introduction of aprepitant. The percentage of patients who achieved CR in the aprepitant group was significantly higher than that in the control group (p = 0.01). Factors that were significantly associated with non-CR included the prophylactic use of aprepitant and chemotherapies containing ≥4 g/m(2)/day of cytarabine. The rates of adverse drug events (ADEs) did not significantly differ between groups. CONCLUSION: The addition of aprepitant to granisetron increased the antiemetic effect without influencing ADEs in patients treated with moderately to highly emetogenic multiday chemotherapy for hematologic malignancies.

    DOI: 10.2146/ajhp120363

    PubMed

  52. Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer 国際誌

    Hiroaki Ikesue

    Chemotherapy   58 巻 ( 6 ) 頁: 419 - 25   2012年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. METHODS: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system. A stepwise logistic regression analysis was performed to identify risk factors for grade 3-4 neutropenia. RESULTS: Of a total 61 patients, 50 were male and 11 were female. The median dose of AMR was 35.0 mg/m(2). The incidence of grade 3-4 neutropenia during the first course was 62%. In multivariate analysis, female gender (OR = 6.68; 95% CI 1.01-134.15; p = 0.049), higher AMR doses (40 mg/m(2) or more) (OR = 5.98; 95% CI 1.77-23.74; p = 0.003), and lower hematocrit values (OR = 2.04 per 5% decrease; 95% CI 1.04-4.38; p = 0.036) were significantly associated with severe neutropenia induced by AMR. CONCLUSION: The present results suggest that female gender, higher doses of AMR, and lower baseline hematocrit values are predictive factors associated with severe neutropenia induced by AMR in patients with advanced lung cancer. Patients who have these predictive factors should be monitored carefully and considered for early granulocyte colony-stimulating factor support.

    DOI: 10.1159/000345617

    PubMed

  53. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation

    Hiroaki Ikesue

    Support Care Cancer     2012年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  54. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction 国際誌

    Hiroaki Ikesue

    Clin J Pain   28 巻 ( 5 ) 頁: 373 - 81   2012年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: The aim of this study was to evaluate the effectiveness of prophylactic treatment with laxatives and antiemetics on the incidence of gastrointestinal adverse reactions such as constipation, nausea and vomiting in cancer patients who received oral opioid analgesics for the first time. METHODS: A multi-institutional retrospective study was carried out, in which 619 eligible hospitalized patients receiving oral opioid analgesics for cancer pain were enrolled from 35 medical institutions. The primary endpoint was the incidence of opioid-induced side effects in patients receiving prophylactic medication. Odds ratios of the incidence of adverse reactions in the absence or presence of premedication obtained from several institutions were subjected to a meta-analysis. RESULTS: Among 619 patients, the incidence of constipation was significantly lower in patients receiving laxatives, including magnesium oxide, as premedication than in those without them (34% vs. 55%, odds ratio=0.432, 95% confidence interval=0.300-0.622, P<0.001). However, the incidence of nausea or vomiting was similar regardless of prophylactic medication with dopamine D2 blockers. The results of the meta-analysis revealed that prophylactic laxatives significantly reduced the incidence of constipation (overall odds ratio=0.469, 95% confidence interval=0.231-0.955, P=0.037), whereas dopamine D2 blockers were not effective in preventing opioid-induced nausea or vomiting. DISCUSSION: We showed evidence for the effectiveness of premedication with laxatives for prevention of opioid-induced constipation. However, premedication with dopamine D2 blockers was not sufficient to prevent nausea or vomiting.

    DOI: 10.1097/AJP.0b013e318237d626

    PubMed

  55. Prevention of oxaliplatin-induced mechanical allodynia and neurodegeneration by neurotropin in the rat model 国際誌

    Hiroaki Ikesue

    Eur J Pain   15 巻 ( 4 ) 頁: 344 - 50   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oxaliplatin is a key drug for colorectal cancer, but it causes acute peripheral neuropathy (triggered by cold) and chronic neuropathy (sensory and motor neuropathy) in patients. Neurotropin, a non-protein extract from the inflamed rabbit skin inoculated with vaccinia virus, has been used to treat various chronic pains. In the present study, we investigated the effect of neurotropin on the oxaliplatin-induced neuropathy in rats. Repeated administration of oxaliplatin caused cold hyperalgesia from Day 5 to Day 29 and mechanical allodynia from Day 15 to Day 47. Repeated administration of neurotropin relieved the oxaliplatin-induced mechanical allodynia but not cold hyperalgesia, and inhibited the oxaliplatin-induced axonal degeneration in rat sciatic nerve. Neurotropin also inhibited the oxaliplatin-induced neurite degeneration in cultured pheochromocytoma 12 (PC12) and rat dorsal root ganglion (DRG) cells. On the other hand, neurotropin did not affect the oxaliplatin-induced cell injury in rat DRG cells. These results suggest that repeated administration of neurotropin relieves the oxaliplatin-induced mechanical allodynia by inhibiting the axonal degeneration and it is useful for the treatment of oxaliplatin-induced neuropathy clinically.

    DOI: 10.1016/j.ejpain.2010.08.006

    PubMed

  56. Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats 国際誌

    Hiroaki Ikesue

    Mol Pain   7 巻   頁: 8 - 8   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. The chronic neuropathy is a dose-limiting toxicity. We previously reported that repeated administration of oxaliplatin induced cold hyperalgesia in the early phase and mechanical allodynia in the late phase in rats. In the present study, we investigated the involvement of NR2B-containing N-methyl-D-aspartate (NMDA) receptors in oxaliplatin-induced mechanical allodynia in rats. RESULTS: Repeated administration of oxaliplatin (4 mg/kg, i.p., twice a week) caused mechanical allodynia in the fourth week, which was reversed by intrathecal injection of MK-801 (10 nmol) and memantine (1 μmol), NMDA receptor antagonists. Similarly, selective NR2B antagonists Ro25-6981 (300 nmol, i.t.) and ifenprodil (50 mg/kg, p.o.) significantly attenuated the oxaliplatin-induced pain behavior. In addition, the expression of NR2B protein and mRNA in the rat spinal cord was increased by oxaliplatin on Day 25 (late phase) but not on Day 5 (early phase). Moreover, we examined the involvement of nitric oxide synthase (NOS) as a downstream target of NMDA receptor. L-NAME, a non-selective NOS inhibitor, and 7-nitroindazole, a neuronal NOS (nNOS) inhibitor, significantly suppressed the oxaliplatin-induced pain behavior. The intensity of NADPH diaphorase staining, a histochemical marker for NOS, in the superficial layer of spinal dorsal horn was obviously increased by oxaliplatin, and this increased intensity was reversed by intrathecal injection of Ro25-6981. CONCLUSION: These results indicated that spinal NR2B-containing NMDA receptors are involved in the oxaliplatin-induced mechanical allodynia.

    DOI: 10.1186/1744-8069-7-8

    PubMed

  57. 再発多発性骨髄腫に対するボルテゾミブ療法における副作用発現頻度と発現時期の調査

    槇枝大貴, 久枝真一郎, 木下英樹, 内田まやこ, 池末裕明, 三嶋一登, 渡邉裕之, 末安正典, 宮本敏浩, 江頭伸昭, 大石了三

    医療薬学   36 巻 ( 4 ) 頁: 270 - 276   2010年4月

     詳細を見る

    記述言語:日本語  

    DOI: 10.5649/jjphcs.36.270

    J-GLOBAL

  58. Stability of cetuximab and panitumumab in glass vials and polyvinyl chloride bags

    Hiroaki Ikesue

    Am J Health Syst Pharm     2010年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  59. Mexiletine reverses oxaliplatin-induced neuropathic pain in rats

    Hiroaki Ikesue

    J Pharmacol Sci   112 巻 ( 4 ) 頁: 473 - 6   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oxaliplatin is a platinum-based chemotherapy drug characterized by the development of acute and chronic peripheral neuropathies. Mexiletine, an orally available Na(+)-channel blocker, has widely been used in patients with chronic painful diabetic neuropathy. In the present study, we examined the effect of mexiletine on oxaliplatin-induced neuropathic pain in rats. Mexiletine (100, but not 10 and 30, mg/kg, p.o.) completely reversed both mechanical allodynia and cold hyperalgesia induced by oxaliplatin (4 mg/kg, i.p., twice a week). Lidocaine (30, but not 3 and 10, mg/kg, i.p.) also significantly relieved both pain behaviors. These results suggest that mexiletine may be effective in relieving the oxaliplatin-induced neuropathic pain clinically.

    PubMed

  60. アントラサイクリン系抗がん剤の投与時間の短縮による血管外漏出の減少

    伊藤 美代, 池末 裕明, 末次 王卓, 内田 まやこ, 三嶋 一登, 佐々木 智啓, 森山 智彦, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 巻 ( 12 ) 頁: 1613 - 1615   2009年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    R-CHOP療法およびR-THP-COP療法において、ドキソルビシン(doxorubicin:以下、DXR)およびピラルビシン(pirarubicin:以下、THP)が血管外に漏出すると重大な皮膚障害を来し得る。九州大学病院消化管内科において心毒性を考慮してDXRおよびTHPを1時間で点滴静注していたが、血管外漏出が続発し、その発現頻度は10.8%(4件/37クール)であった。一方、放射線科ではDXRおよびTHPを5分以内で静脈内注射しており、血管外漏出は発現していなかった(0件/36クール)。そこで、血管外漏出の要因分析および文献調査を行い、投与方法についてカンファレンス等で協議し5分以内での静脈内注射へ変更したところ、その後血管外漏出は発現しなかった(0件/28クール)。DXRおよびTHPを5分以内で静脈内注射することで血管外漏出のリスクが著明に軽減されることが明らかとなった。(著者抄録)

    J-GLOBAL

  61. 化学放射線療法における患者理解度向上のための服薬指導シートの改善

    内田 まやこ, 池末 裕明, 伊藤 美代, 藤原 朋子, 三嶋 一登, 末安 正典, 江頭 伸昭, 大石 了三

    日本病院薬剤師会雑誌   45 巻 ( 2 ) 頁: 247 - 250   2009年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    今回我々は、がん化学療法および化学放射線療法に対する患者の理解を高めるとともに、患者自身によるセルフケアの支援を目指して、薬剤管理指導業務の際に使用する服薬指導シートの改善を行った。改善点としては、記載内容である投与スケジュール、薬効および副作用に副作用の好発時期を追加し、従来の文章中心の様式から、より視覚的に理解しやすいものに変更した。実際に、九州大学病院の放射線科病棟において薬剤管理指導業務を行う際に新様式の服薬指導シートを患者に交付し、これを基に服薬指導を行ったところ、患者および医療スタッフには大変好評であった。特に、患者には治療に対する理解が深まり、不安の軽減とともに治療への意欲向上にもつながると思われる。さらに、医師および看護師との情報交換も増加し、患者情報および薬剤情報の共有化にも有用であると考えられた。(著者抄録)

    J-GLOBAL

  62. 質疑応答事例の解析による医薬品情報ニーズの把握と応用

    坂井 真樹, 池末 裕明, 山本 香代子, 富吉 由貴, 國分 千代, グリム 理恵子, 高田 敦史, 園田 正信, 川重 誠, 江頭 伸昭, 大石 了三

    医療薬学   35 巻 ( 3 ) 頁: 161 - 166   2009年

     詳細を見る

    記述言語:日本語   出版者・発行元:日本医療薬学会  

    The importance of providing drug information has increased with the expansion of pharmaceutical care. In order to provide appropriate drug information to healthcare professionals, pharmacists have to understand their needs in this respect and be familiar with the procedure for answering typical questions. In the present study, we analyzed all of the questions (9,999) recorded by the drug information center of Kyushu University Hospital and the answers to them in the period from 2001 to 2007. The questions were from doctors (59.3%), pharmacists (21.5%), nurses (15.4%), and others (3.9%). The most frequent questions were on compatibility and stability of injections (18.8%), selecting drugs (13.2%), and dosage and administration (9.8%). We therefore made information on the compatibility and stability of injections available to other pharmacists via our intranet. We felt it was useful to clarify healthcare professionals' needs for drug information and develop a system enabling drug information to be used more easily.

    DOI: 10.5649/jjphcs.35.161

    CiNii Books

    その他リンク: https://jlc.jst.go.jp/DN/JALC/00327895853?from=CiNii

  63. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. 国際誌

    Hiroaki Ikesue

    Pain   147 巻 ( 1-3 ) 頁: 165 - 74   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Oxaliplatin is a key drug in the treatment of advanced metastatic colorectal cancer, but it causes acute peripheral neuropathy (acral paresthesias triggered by exposure to cold) and chronic neuropathy (abnormal of sensory and motor dysfunction). Oxaliplatin is metabolized to oxalate and dichloro(1,2-diaminocyclohexane)platinum (Pt(dach)Cl(2)). Although the chelating of Ca(2+) with oxalate eliminated from oxaliplatin is thought as one of the reasons for the neuropathy, there is little behavioral evidence. In this study, we investigated the involvement of oxalate in the oxaliplatin-induced peripheral neuropathy in rats. Oxaliplatin (4mg/kg, i.p., twice a week) induced cold hyperalgesia/allodynia (cold-plate and acetone tests) in the early phase, and mechanical allodynia (von Frey test) in the late phase. Oxalate (1.3mg/kg, i.p., twice a week) induced the cold hyperalgesia/allodynia in the early phase, but did not induce the mechanical allodynia. On the other hand, Pt(dach)Cl(2) (3.8mg/kg, i.p., twice a week) induced the mechanical allodynia in the late phase, but did not induce the cold hyperalgesia/allodynia. The pre-administration of calcium or magnesium (0.5mmol/kg, i.v.) before oxaliplatin or oxalate prevented the cold hyperalgesia but not mechanical allodynia. However, the treatment with calcium or magnesium after the development of neuropathy could not attenuate the cold hyperalgesia or mechanical allodynia. These findings suggest the involvement of oxalate in oxaliplatin-induced cold hyperalgesia but not mechanical allodynia, and usefulness of prophylactic treatments with calcium and magnesium on the acute peripheral neuropathy.

    DOI: 10.1016/j.pain.2009.09.003

    PubMed

  64. Protection against the extravasation of anticancer drugs by standardization of the management system

    Hiroaki Ikesue

    Hosp Pharm     2008年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1310/hpj4307-571

  65. Oncology pharmacy specialists in oncology

    Hiroaki Ikesue, Ryozo Oishi

    Gan to kagaku ryoho. Cancer &amp; chemotherapy   35 巻 ( 4 ) 頁: 578 - 582   2008年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    To provide effective and safe cancer treatment, the medical staff must form a team with patients and their family. Pharmacists have to be responsible for verifying chemotherapy prescription orders, mixing of anticancer drugs, management of adverse drug reactions, patient education, while providing drug information and participation in palliative care. To promote pharmacists who have acquired advanced knowledge and skills, The Japanese Society of Hospital Pharmacists started and educational program and established the certification of board-certified oncology pharmacy specialists (BCOPS) and board-certified pharmacists in oncology pharmacy (BCPOP). As of November 2007, 56 pharmacists were qualified as BCOPS.

    Scopus

    PubMed

  66. 進行および再発食道がんに対するLow dose FP放射線同時併用療法における副作用管理

    内田 まやこ, 野尻 宣仁子, 村上 裕子, 山路 寛子, 池末 裕明, 三嶋 一登, 古賀 友一郎, 末安 正典, 吉川 学, 伊藤 善規, 大石 了三

    日本病院薬剤師会雑誌   43 巻 ( 3 ) 頁: 361 - 364   2007年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    我々はこれまで、抗がん剤による副作用頻度や発現時期について文献的に調査することにより、種々の化学療法レジメンに対応したがん化学療法ワークシートを作成し、確実かつ効率的な薬剤管理指導業務の実践に役立ててきた。しかしながら、この方法は通常とは異なる用量、もしくは用法の化学療法レジメン、あるいは放射線との併用療法(化学放射線療法)には対応できていなかった。今回、九州大学病院放射線科にてLow dose FP放射線併用療法が行われた16人の食道がん患者に対して薬剤管理指導業務を実施し、そのなかで副作用の発現状況について詳しく調査するとともに、予防もしくは治療のための対策など薬学的関与の必要性について検討した。また、これらのデータを基に、より効率的かつ質の高い薬剤管理指導業務を支援するための処方チェック・副作用モニタリングシートを作成した。(著者抄録)

    J-GLOBAL

  67. Evaluation of Effectiveness of New Infusion Set Equipped with an In-line Filter :

    Itoh Yoshinori, Sendo Toshiaki, Nakatsune Emi, Hirakawa Yoshihiro, Ikesue Hiroaki, Oishi Ryozo

    医療薬学   32 巻 ( 12 ) 頁: 1228 - 1235   2006年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:日本医療薬学会  

    In the present study, we evaluated the effectiveness of a new infusion set equipped with an in-line filter (5μm pore size) in removing precipitates of foreign matter forming during or after the preparation of infusion fluids. We also examined the ability of the new infusion set to prevent adverse effects associated with the intravenous injection of fluids containing crystalline precipitates in rats. The number of particles and their sizes were measured for two infusion fluids administered using a conventional infusion set without an in-line filter and the new infusion set, collecting the samples for measurement from the outlets of the respective infusion sets. One of fluids was a glycyrrhizin solution prepared from a glass ampoule injection, and the other etoposide solution prepared by diluting a preparation of this solution in a vial with saline. A number of particles (>10μm in size) were detected for both infusion fluids when administered by the conventional infusion set but none were detected in them when administered by the new infusion set. The intravenous injection of the precipitate-containing etoposide solution from the conventional infusion set to rats caused marked extravasation of plasma proteins and edema in lungs. Such adverse reactions did not occur with the new infusion set, demonstrating that it was effective in removing paniculate matter. It should thus be useful in intravascular fluid therapy from the safety point of view.

    DOI: 10.5649/jjphcs.32.1228

    CiNii Books

    その他リンク: https://jlc.jst.go.jp/DN/JALC/00288531470?from=CiNii

  68. Ovariectomy aggravates hypersensitivity reactions to paclitaxel in rats 国際誌

    Hiroaki Ikesue

    Cancer Biol Ther   4 巻 ( 2 ) 頁: 225 - 30   2005年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The incidence of hypersensitivity reactions is still a matter of serious concern during chemotherapy with paclitaxel, particularly in patients with ovarian cancer. We recently reported that intravenous injection of paclitaxel causes acute lung injury characterized by vascular hyperpermeability, edema and respiratory dysfunction in rats. In the present study, we investigated the influence of ovariectomy on the paclitaxel-induced acute lung injury in rats. Ovariectomy worsened paclitaxel-induced acute lung injury, which was reversed by 17beta-estradiol. The mRNA expression for endothelial nitric oxide synthase was reduced in lungs of ovariectomized rats. To determine the role for nitric oxide, we examined the effects of several agents that modulate nitric oxide concentration on the pulmonary response to paclitaxel. In ovary-intact rats, a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester exaggerated paclitaxel-induced acute lung injury, while nitric oxide donors such as sodium nitroprusside and isosorbide dinitrate attenuated the lung injury. Sodium nitroprusside was also effective in alleviating the paclitaxel-induced acute lung injury in ovariectomized rats. These findings suggest that ovariectomy enhances the susceptibility to paclitaxel hypersensitivity, in which decrease in estrogen and subsequent reduction in nitric oxide synthesis may be involved.

    PubMed

  69. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy.

    Hiroaki Ikesue

    Cancer Chemother Pharmacol     2005年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  70. Monitoring for potential adverse drug reactions in patients receiving chemotherapy. 国際誌

    Hiroaki Ikesue

    Am J Health Syst Pharm   61 巻 ( 22 ) 頁: 2366, 2368-9   2004年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PubMed

  71. Increased topical tacrolimus absorption in generalized leukemic erythroderma.

    Hiroaki Ikesue

    Ann Pharmacother     2003年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

  72. Involvement of glial cells in cyclosporine-increased permeability of brain endothelial cells.

    Hiroaki Ikesue

    Cell Mol Neurobiol     2000年

     詳細を見る

    掲載種別:研究論文(学術雑誌)  

    PubMed

▼全件表示

MISC 12

  1. ラムシルマブ投与患者における蛋白尿発現のリスク因子に関する検討

    田中 智也, 蔵田 靖子, 高瀬 尚武, 樋本 繭子, 新免 徹, 檀 和貴, 鍛治園 誠, 正岡 康幸, 中本 秋彦, 名和 秀起, 北村 佳久, 池末 裕明, 室井 延之, 千堂 年昭, 三木 育子  

    医療薬学47 巻 ( 5 ) 頁: 250 - 255   2021年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本医療薬学会  

    ラムシルマブ(RAM)投与前に蛋白尿を認めなかった患者群を対象に、RAM投与後に蛋白尿2+以上の発現に影響を与えるリスク因子を評価した。対象患者は86例であり、男性53例、女性33例であった。対象患者86例中、蛋白尿1+以上を認めた患者は54例(64.3%)、そのうち蛋白尿2+以上を認めた患者は21例(24.4%)であった。RAM投与時における蛋白尿2+以上の発現に関するリスク因子を検索するため単変量解析を行った。その結果、RAM投与開始時点で降圧薬を併用およびベバシズマブ(BV)投与歴ありについて統計学的に有意差が認められた。多変量解析で有意な関連を認めた2項目について多変量Cox比例ハザードモデルにて解析を行った。その結果、BV投与歴が蛋白尿2+以上の発現に有意に関連する因子であった。BV投与歴が蛋白尿2+以上の発現リスクを有意に上昇させることが示されたため、BV投与歴の有無とRAM投与開始後に蛋白尿2+以上を認めるまでの期間をカプラン・マイヤー曲線で示した。BV投与歴を有する患者ではより早期に蛋白尿2+以上を認めた。さらに、RAM投与期間中における蛋白尿の程度を比較すると、BV投与歴を有する患者群およびBV投与歴のない患者群における蛋白尿1+以上の発現率はそれぞれ69.0%および59.7%であった。さらに蛋白尿2+以上の発現率はそれぞれ41.4%および15.8%で、BV投与歴を有する患者群で有意に高かった。BV投与時に蛋白尿を認めた10例および認めなかった19例における、RAM投与時に蛋白尿2+以上を発現した割合はそれぞれ40.0%(4/10)および42.1%(8/19)であった。

    J-GLOBAL

    その他リンク: https://search-tp.jamas.or.jp/index.php?module=Default&action=Link&pub_year=2021&ichushi_jid=J03520&link_issn=&doc_id=20210519230004&doc_link_id=1390573571403075328&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1390573571403075328&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_3.gif

  2. オピオイド鎮痛薬による消化器系副作用対策に関する多施設共同研究(J-RIGID study)のサブ解析 各県における緩下剤処方状況と評価

    石原 正志, 池末 裕明, 千堂 年昭, 荒木 博陽, 伊藤 善規  

    日本病院薬剤師会雑誌50 巻 ( 9 ) 頁: 1117 - 1121   2014年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    我々は、多施設共同研究においてすでにオピオイド鎮痛薬による便秘(以下、OIC)に対する緩下剤予防投与の有用性を報告した。本研究は、その多施設共同研究のデータを用いたサブ解析である。その結果、各県で緩下剤の予防投与の頻度や処方内容が異なり、各県のOIC発現率は緩下剤予防投与率と逆相関していた。また、4県のメタ解析では、緩下剤予防投与はOICのオッズを有意に減少させた。緩下剤の内容は、いずれの県でも酸化マグネシウム(以下、MgO)が高頻度に使用され、岐阜県を除く3県では錠剤の処方頻度が高かったのに対し、岐阜県では散剤の単独もしくは他剤との併用が多くみられた。しかし、岐阜県でみられたMgOにパンテチン(pantethin:以下、PAN)を併用した処方はMgO単剤投与に比べ、OIC発現率を低下させなかった。以上より、各県での解析結果でも緩下剤のOIC予防効果が確認されたが、緩下剤としてのPAN併用の有用性は証明されなかった。(著者抄録)

  3. 内服強オピオイド鎮痛薬投与時の緩下剤および制吐剤予防投与の有用性評価に関する多施設共同研究:J-RIGID study

    石原 正志, 池末 裕明, 松永 尚, 末丸 克矢, 北市 清幸, 大石 了三, 千堂 年昭, 荒木 博陽, 伊藤 善規  

    日本薬学会年会要旨集132年会 巻 ( 4 ) 頁: 193 - 193   2012年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本薬学会  

  4. Involvement of TRPM8 activation via Ca2+ channel/NFAT pathway in oxaliplatin-induced cold hyperalgesia

    Kentaro Kurobe, Takehiro Kawashiri, Nobuaki Egashira, Yuji Yamashita, Kuniaki Tsutsumi, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES115 巻   頁: 233P - 233P   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  5. Effect of NR2B antagonist and amitriptyline on oxaliplatin-induced peripheral neuropathy

    Hikaru Sada, Nobuaki Egashira, Yuki Mihara, Takehiro Kawashiri, Soichiro Ushio, Masafumi Shirahama, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES115 巻   頁: 278P - 278P   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  6. Involvement of noradrenergic and serotonergic systems in the analgesic effect of neurotropin on the oxaliplatin-induced neuropathic pain

    Hitomi Watanabe, Takehiro Kawashiri, Nobuaki Egashira, Ken Masuguchi, Yoko Tashushima, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES115 巻   頁: 127P - 127P   2011年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  7. Role of Substance P in paclitaxel-induced neuropathy in rats-comparison with oxaliplatin

    Yoko Ikegami, Nobuaki Egashira, Takehiro Kawashiri, Yuki Mihara, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES112 巻   頁: 219P - 219P   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  8. Involvement of spinal NMDA receptor in oxaliplatin-induced peripheral neuropathy in rats

    Yuki Mihara, Nobuaki Egashira, Takehiro Kawashiri, Hikaru Sada, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES112 巻   頁: 112P - 112P   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  9. Neurotropin ameliorates oxaliplatin-induced peripheral neuropathy in rats

    Takehiro Kawashiri, Nobuaki Egashira, Hitomi Watanabe, Shingo Hirakawa, Yoko Ikegami, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES112 巻   頁: 218P - 218P   2010年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  10. Further study on the involvement of oxalate in the oxaliplatin-induced peripheral neuropathy in rats

    Takehiro Kawashiri, Nobuaki Egashira, Mariko Sakurai, Takahisa Yano, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES109 巻   頁: 173P - 173P   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  11. Effect of mexiletine on oxaliplatin-induced neuropathy in rats

    Shingo Hirakawa, Nobuaki Egashira, Takahisa Yano, Takehiro Kawashiri, Hiroaki Ikesue, Ryozo Oishi  

    JOURNAL OF PHARMACOLOGICAL SCIENCES109 巻   頁: 174P - 174P   2009年

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:JAPANESE PHARMACOLOGICAL SOC  

    Web of Science

  12. 心臓カテーテル検査における「お薬説明書」を用いた薬剤管理指導の有用性 ヨード造影剤の遅発性副作用による不安を軽減するために

    内田 まやこ, 安藝 敬生, 白水 景子, 池末 裕明, 三嶋 一登, 末安 正典, 千堂 年昭, 吉川 学, 伊藤 善規, 大石 了三  

    日本病院薬剤師会雑誌42 巻 ( 3 ) 頁: 347 - 350   2006年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本病院薬剤師会  

    著者らは心臓カテーテル検査に使用される薬剤の「お薬説明書」を作成し,これを循環器内科の入院患者に用い,服薬指導を行なっている。そこで,これらを踏まえて,「お薬説明書」の有用性ならびに服薬指導の必要性について患者アンケート調査を行なった.その結果,検査前に医師より説明を受けているのにもかかわらず,服薬指導によってはじめて造影剤による遅発性副作用を知ったと答えた患者は65%もいた.また,一方で副作用に対する不安が軽減されたと答えた患者は68%いた.以上,これらのことから,心臓カテーテル検査において「お薬説明書」を用いた服薬指導は有用であると示唆された

▼全件表示

講演・口頭発表等 20

  1. (特別講演)地域につなぐ薬物療法と薬剤師の役割~ツールの活用と具体例~ 招待有り

    池末裕明

    日本医療薬学会第79回医療薬学公開シンポジウム  2021年6月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

  2. チームで支えるirAEマネジメント 招待有り

    池末裕明

    日本臨床腫瘍学会 がん免疫薬物療法マネジメントセミナーベーシックコース  2022年2月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  3. チームで支えるirAEマネジメントとタスクシフト 招待有り

    池末裕明

    日本臨床腫瘍学会 がん免疫薬物療法マネジメントセミナーアドバンスドコース  2022年6月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  4. 安全ながん薬物療法の実践 招待有り

    池末裕明

    日本医療薬学会・日本病院薬剤師会 がん専門薬剤師集中教育講座  2022年8月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  5. (Basicセミナー)免疫関連有害事象(irAE)とその対策 招待有り

    池末裕明

    日本臨床腫瘍薬学会学術大会2020  2020年3月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  6. (シンポジウム基調講演)外来から入院、そして地域とつなぐ 薬物療法と薬剤師の役割 招待有り

    池末裕明

    第81回九州山口薬学大会  2022年9月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  7. (シンポジウム)Oncology pharmacistの役割の広がりと深化 招待有り

    池末裕明

    医療薬学フォーラム2021/第29回クリニカルファーマシーシンポジウム  2021年7月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  8. (シンポジウム)がん専門薬剤師の視点から:エビデンス発信と臨床研究教育 招待有り

    池末裕明

    日本薬学会第140年会  2020年3月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  9. (シンポジウム)がん薬物療法における薬剤師の役割:深化と広がり 招待有り

    池末裕明

    第41回日本病院薬剤師会近畿学術大会  2020年2月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  10. (シンポジウム)共に学び伴走する一般病院での研究支援~頼れる先輩薬剤師を目指して~ 招待有り

    池末裕明

    第30回日本医療薬学会年会  2020年10月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  11. (シンポジウム)新たな展開を迎えたがん薬物療法を支える薬剤師の育成と広がり 招待有り

    池末裕明

    日本臨床腫瘍薬学会学術大会2020  2020年3月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  12. (シンポジウム)臨床現場で取り組むエビデンス創出と人材育成 招待有り

    池末裕明

    日本臨床腫瘍薬学会学術大会2021  2021年3月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  13. (シンポジウム)試験委員会の立場から~求められる知識とは~ 招待有り

    池末裕明

    第5回日本病院薬剤師会 Future Pharmacist Forum  2022年7月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  14. (シンポジウム)院内・地域との連携をとおして共に学ぶ~育成の舞台裏~ 招待有り

    池末裕明

    第32回 日本医療薬学会年会  2022年9月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  15. (教育講演)支持療法 招待有り

    池末裕明

    第59回日本癌治療学会学術集会  2021年10月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  16. (特別講演)がん薬物療法における安全性の向上とエビデンスの発信 招待有り

    池末裕明

    第42回日本薬学会九州山口支部コロキウム  2021年9月 

     詳細を見る

    会議種別:口頭発表(招待・特別)  

  17. がん免疫療法(免疫チェックポイント阻害薬)による有害事象と支持療法 招待有り

    池末裕明

    日本臨床腫瘍薬学会 Essential Seminar Neo 2022 C-Program  2022年8月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

  18. (Symposium) Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. 招待有り

    Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, Matsumoto K, Inoue M, Satake R, Yoshida Y, Goto F, Hashida T, Nakamura M

    第30回日本医療薬学会年会  2020年10月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  19. (Symposium) Big data analytics and pharmacovigilance: a retrospective study using the Japanese Adverse Drug Event Report (JADER) database 招待有り

    Hasegawa S, Ikesue H, Iguchi K, Hashida T, Nakamura M

    The Asia-Pacific Symposium on Drug Development and Digital Innovation  2020年10月 

     詳細を見る

    会議種別:シンポジウム・ワークショップ パネル(指名)  

  20. がん免疫療法(免疫チェックポイント阻害薬)による副作用と支持療法 招待有り

    池末裕明

    日本臨床腫瘍薬学会Essential Seminar Neo 2021 C-Program  2021年8月 

     詳細を見る

    会議種別:公開講演,セミナー,チュートリアル,講習,講義等  

▼全件表示

科研費 10

  1. 免疫チェックポイント阻害薬の副作用早期発見のための指標と安全な診療体制の確立

    研究課題/研究課題番号:23K06251  2023年4月 - 2026年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

      詳細を見る

    担当区分:研究代表者 

  2. がん骨転移治療薬による副作用の早期発見と対策法の開発

    研究課題/研究課題番号:18K06770  2018年4月 - 2021年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    骨転移を有するがん患者では、がん治療に加えて骨転移に伴う諸症状の予防と対策が加わるため複雑になる。より安全ながん薬物療法の実施に向け、副作用の早期発見と対策法の開発を推進する必要がある。そこで、骨転移治療薬による顎骨壊死のリスク因子を評価した。
    さらに、がん薬物療法による副作用のリスク因子について検討し、また、免疫チェックポイント阻害薬による治療をより安全に実施するため、事前に取り決めたプトロコールに基づき薬剤師が薬物療法を支援する体制を構築し、その有用性を評価した。本研究の結果は、より安全で持続可能ながん薬物療法のため、有益な情報を提供するものと考えられた。

  3. 多発性骨髄腫患者におけるレナリドミドの副作用発現に及ぼす影響因子の解明

    研究課題/研究課題番号:16H07349  2016年8月 - 2018年3月

    日本学術振興会  科学研究費助成事業  研究活動スタート支援

    内田 まやこ, 山下 花南恵, 池末 裕明, 橋田 亨

      詳細を見る

    多発性骨髄腫(MM)の予後は、免疫調整薬など新規薬剤の導入により改善している。レナリドミド(LEN)およびデキサメタゾンの併用療法(Ld療法)は、高い有効性が示されており、広く行われている。しかしながら、しばしば好中球減少をきたし、重篤な感染症を発現するリスクがある。本研究では、Ld療法における重篤な好中球数減少の危険因子について検討した。治療開始前の好中球数が低値である患者は、重篤な好中球数減少の発現頻度が高いことが示された。治療前の好中球数が低いハイリスク患者では好中球数をより慎重にモニタリングすべきであることが示唆された。

  4. 腎機能評価に基づく癌骨転移治療薬による副作用の早期発見と対策法の開発

    研究課題/研究課題番号:15K08591  2015年4月 - 2018年3月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    池末 裕明, 増田 智先

      詳細を見る

    担当区分:研究代表者 

    配分額:4940000円 ( 直接経費:3800000円 、 間接経費:1140000円 )

    がんの骨転移に対してゾレドロン酸を投与した成人がん患者236名を対象に、後方視的に腎障害のリスク因子解析を行った。腎障害の発現頻度は13%であった。多変量解析の結果、糖尿病の既往、腎機能低下およびシスプラチン併用が有意なリスク因子であった。また、悪性黒色腫に対するダブラフェニブ・トラメチニブ併用療法により急性腎障害を認めた症例を報告した。さらに、骨転移治療薬を使用した成人がん患者397名を対象に、顎骨壊死の発症率とリスク因子を後方視的に調査した。顎骨壊死の発現率は6%であった。多変量解析の結果、デノスマブ投与、高齢、血管新生阻害薬併用が、顎骨壊死の有意なリスク因子であった。

  5. がん骨転移治療におけるゾレドロン酸誘発腎障害回避に向けた薬学的介入の評価

    研究課題/研究課題番号:26929030  2014年4月 - 2015年3月

    日本学術振興会  科学研究費助成事業  奨励研究

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:600000円 ( 直接経費:600000円 )

    【目的】進行がんに対する治療法の進歩により余命が延長し、長期間の骨転移治療を要する患者が増えている。ゾレドロン酸(ZA)は重要な骨転移治療薬であるが、腎障害が重篤な副作用であり、ときに積極的な治療を妨げる。一方、骨転移に対してZAと並んで頻用されるデノスマブ(Dmab)では、腎障害は稀だが重篤な低Ca血症に注意が必要である。これらのことから、より安全性の高い骨転移治療を可能にするため、ZAによる腎障害およびDmabによる低Ca血症発現リスクの正確な評価と、ZA誘発腎障害の回避に向けた処方支援策の評価を目的とした。
    【方法】九州大学でZAまたはDmabによる骨転移治療を受けた成人がん患者416名を対象に、レトロスペクティブにデータを収集し患者背景とZAによる腎障害、およびDmabによる低Ca血症の発現リスクについて検討し、薬学的観点から機序を検討した。また、ZAは患者の腎機能に応じ投与量が推奨されているため、処方監査の際に薬剤師からの疑義照会を強化した。なお本研究は、九州大学医系地区部局臨床研究倫理審査委員会の承認を得て実施した。
    【成果】ZAによる腎障害の発現リスクは、ZA開始時に腎機能が既に低下している患者、高血圧を合併している患者で有意に高かった。腎機能低下患者における薬学的介入策として、ZAからDmabへの変更が有用である可能性があるが、腎機能低下患者ではDmabによる低Ca血症の発現リスクも高く、血清Ca値の厳重なモニタリングが不可欠であると考えられた。また、ZAが使用された患者350例のうち、90%で腎機能に基づく厳密な投与量が処方された。これは従来の報告に比べ高い割合であり、薬剤師による処方支援の有用性が確認された。

  6. 骨転移治療における腎機能別ビスホスホネート系薬剤の適正使用法確立

    2013年4月 - 2014年3月

    臨床薬理研究振興財団  研究助成事業  研究奨励金

      詳細を見る

    担当区分:研究代表者 

  7. がん化学療法に関する質疑応答データベースの解析に基づく調査回答マニュアルの作成

    研究課題/研究課題番号:19923002  2007年4月 - 2008年3月

    日本学術振興会  科学研究費助成事業  奨励研究

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:660000円 ( 直接経費:660000円 )

    【目的】近年、多くの医療施設で多職種からなるがんチーム医療が実践されている。その中で、薬剤師による様々な医薬品情報の提供は、他の医療スタッフが薬剤師に求める重要な役割の一つである。ところがこれまで、がん化学療法において医療スタッフの求める医薬品情報を客観的に解析した研究はなく、また、適切な情報を収集し効果的に提供する方法論も確立されていないことから、提供する情報の内容は、個々の薬剤師の経験と能力に依存しているのが現状である。そこで、がん化学療法における薬剤師への質疑応答内容を解析することで、医薬品情報に関するニーズを明らかにし、さらに典型的な質問に対する調査回答マニュアルの作成を通して、薬剤師による医薬品情報提供の標準化を目指した。
    【方法と成果】2001年から2007年に医療スタッフから薬剤師に寄せられ、九州大学病院薬剤部のデータベースに蓄積されていた全ての質疑応答事例について、その内容の詳細を解析した。質問総数は9999件で、このうちがん化学療法に関する質問は1146件であった。全ての領域では、注射剤の製剤学的情報、治療上の薬の選択および用法・用量に関する質問が多く、がん化学療法では副作用に関する情報が強く求められる傾向にあった。さらに副作用に関する事例を細分類したところ、骨髄抑制に関する質問が最も多く、次いで口内炎、悪心・嘔吐、血管外漏出に関するものが多かった。これらの副作用への問い合わせについては、これまで、国内外の報告やガイドライン等を網羅的に調査し、回答していたが、本検討では、解析結果に基づいて典型事例を抽出し、調査回答マニュアルを作成した。マニュアルは、情報提供時に取り扱いが容易な様にラミネート加工したほか、新人薬剤師の教育資料として活用した。その結果、薬剤師の情報提供能力の向上や均一化につながり、がんチーム医療の質向上に大きく寄与したことが考えられた。

  8. 抗悪性腫瘍薬パクリタキセルによる末梢神経障害に対するクーリングの予防効果の検討

    研究課題/研究課題番号:18923003  2006年4月 - 2007年3月

    日本学術振興会  科学研究費助成事業  奨励研究

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:730000円 ( 直接経費:730000円 )

  9. 広汎ながん化学療法プロトコールに対応するワークシートのデータベース化

    研究課題/研究課題番号:16922043  2004年4月 - 2005年3月

    日本学術振興会  科学研究費助成事業  奨励研究(B)

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:700000円 ( 直接経費:700000円 )

  10. 高度視覚障害者へのCD装置を用いた情報提供の検討

    研究課題/研究課題番号:12922129  2000年4月 - 2001年3月

    日本学術振興会  科学研究費助成事業  奨励研究(B)

    池末 裕明

      詳細を見る

    担当区分:研究代表者 

    配分額:270000円 ( 直接経費:270000円 )

▼全件表示